Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer
• •* Recurrent disease (any FIGO stage)
• •* Not amenable to curative surgery or radiotherapy alone
• •Failed prior primary platinum-based therapy at least 6 months after therapy discontinuation
• •Measurable lesion by CT scan, MRI, chest x-ray, or sonography
• •* Physical examination allowed for documenting lymph node and skin metastases
• •* Physical gynecological examination allowed for well-defined palpable tumor lesions
• •* Increase in CA 125 without any measurable tumor is not acceptable as indication of recurrence
• •No CNS metastases
• •No tumor of borderline malignancy
• •PATIENT CHARACTERISTICS:
• •Age
• •18 to 65
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 24 weeks
• •Hematopoietic
• •Neutrophil count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •Hepatic
• •Not specified
• •Renal
• •Creatinine clearance at least 60 mL/min
• •No chronic or acute renal failure
• •Cardiovascular
• •Cardiovascular function sufficient for hyperthermia treatment by stress-ECG
• •No cardiomyopathy with impaired ventricular function
• •No New York Heart Association class III or IV heart disease
• •No cardiac arrhythmias influencing LVEF and requiring medication
• •No myocardial infarction or angina pectoris within the past 6 months
• •No uncontrolled arterial hypertension
• •Pulmonary
• •Pulmonary function sufficient for hyperthermia treatment by pulmonary function tests
• •Other
• •No untreated endocrinological disease (e.g., hyperthyroidism or diabetes mellitus)
• •No other primary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer
• •No contraindication against hyperthermia treatment (e.g., photodermatosis, history of malignant hyperthermia, or claustrophobia)
• •No hypersensitivity to carboplatin, ifosfamide, or any other study medication
• •Not pregnant or nursing
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •See Disease Characteristics
• •No concurrent cytotoxic or other antineoplastic therapy
• •Endocrine therapy
• •Concurrent hormone replacement therapy allowed
• •Concurrent steroid antiemetics allowed
• •Radiotherapy
• •See Disease Characteristics
• •At least 1 year since prior radiotherapy (tumoricidal dose) of the pelvis
• •Concurrent palliative local radiotherapy for painful (nonprogressive) existing lesion is allowed if other measurable sites are present
• •No concurrent radiotherapy to a second existing lesion
• •Surgery
• •See Disease Characteristics
• •Other
• •No prior form of hyperthermic therapy
• •At least 3 weeks since other medications as part of another clinical study
• •At least 3 weeks since prior investigational agents
• •At least 6 weeks since prior betablockers
• •No concurrent photosensitizing drugs
• •No concurrent betablockers
• •No other concurrent anticancer therapy